Media Coverage
Boosting Hamburg as a Science and Pharmaceutical Location Together With BioAgilytix
Andreas Rieckhof, State Councilor for Economic Affairs, LSN Managing Director Dr. Jürgen Walkenhorst and Juliane Worm, LSN Director Innovation & Technologies, visited the European headquarters…
Pre-existing Immunogenicity: How Will Cell and Gene Therapies Change Our Testing Approach?
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave of C>s entering the development…
Bioanalytical Needs And Biosimilars: How Does The Molecule Compare?
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions of this product to enter…
Trends Paving The Way For An Influx Of Biosimilar Development
Promising broader patient access to critical medicines, biosimilars offer a more cost-effective alternative therapeutic option compared with originator products. With many patents for blockbuster” commercial…
Overcoming Bioanalytical Hurdles In The Pharma And Life Sciences Sector
Summary Jim McNally’s article, ‘Overcoming bioanalytical hurdles in the pharma and life sciences sector,’ is now available in Manufacturing Chemist magazine: Click for full article
TBJ Reveals the 2020 Fast 50 Award Winners
BioAgilytix has recently been awarded the 2020 Fast 50 Award by Triangle Business Journal as one of the fastest-growing private companies within our region.
Analytical Assays Determine Biosimilar Product Quality
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical assays needed to determine and…
Analytical Assays Determine Biosimilar Product Quality
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical assays needed to determine and ensure…
Triangle-based BioAgilytix Acquires Cambridge CRO, Plans Hiring, More Acquisitions
North Carolina Biotechnology Center covers BioAgilytix’s recent acquisition of Cambridge Biomedical in the world’s major biotech center, as well as its plans for future hiring…
Riverside Partners to Score 7.4-Times Return on BioAgilytix
Riverside Partners is set to earn a lofty return from its sale of BioAgilytix Labs LLC, a Durham, N.C.-based provider of molecular bioanalysis services. The…